Biological responsiveness to first injections of interferon-beta in patients with multiple sclerosis
- 7 October 2004
- journal article
- clinical trial
- Published by Elsevier in Journal of Neuroimmunology
- Vol. 158 (1-2) , 195-203
- https://doi.org/10.1016/j.jneuroim.2004.08.006
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Biological activity of interferon betas in patients with multiple sclerosis is affected by treatment regimen and neutralising antibodiesJournal of Neurology, Neurosurgery & Psychiatry, 2004
- Neutralizing antibodies against IFN- in multiple sclerosis: antagonization of IFN- mediated suppression of MMPsBrain, 2004
- Persistent neutralizing antibodies abolish the interferon β bioavailability in MS patientsNeurology, 2003
- A randomized, double-blind, dose-comparison study of weekly interferon β-1a in relapsing MSNeurology, 2002
- Interferon‐Induced Mx Proteins: Dynamin‐Like GTPases with Antiviral ActivityTraffic, 2002
- Evaluation of IFNα bioavailability by MxA mRNA in HCV patientsJournal of Immunological Methods, 2002
- Evaluation of bioavailability of three types of IFNβ in multiple sclerosis patients by a new quantitative-competitive-PCR method for MxA quantificationJournal of Immunological Methods, 2001
- A comparative study of the relative bioavailability of different interferon beta preparationsNeurology, 2000
- Mx proteins in blood leukocytes for monitoring interferon beta-1b therapy in patients with MSNeurology, 2000
- Bioavailability of interferon beta 1b in MS patients with and without neutralizing antibodiesNeurology, 1999